Use of Real-World Data in Cost-Effectiveness Analysis of Sequential Biologic Treatment for Rheumatoid Arthritis by [email protected] | Oct 30, 2023
Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: bayesian evidence synthesis with target trial emulation by [email protected] | Oct 16, 2023
Reasons for initiating canakinumab among patients with systemic juvenile idiopathic arthritis and adult-onset Still’s disease in the United States real-world settings by [email protected] | Oct 16, 2023
